Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Comparative evaluation of antiarrhythmic agents.

J Morganroth

    Drugs
    |January 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    New antiarrhythmic drugs, like the class Ic

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    A thorough electrocardiogram study of edoxaban, a novel factor Xa inhibitor.

    Journal of clinical pharmacology·2011
    Same author

    Effects of the selective alpha 1a-adrenoceptor antagonist silodosin on ECGs of healthy men in a randomized, double-blind, placebo- and moxifloxacin-controlled study.

    Clinical pharmacology and therapeutics·2010
    Same author

    Evaluation and management of cardiac safety using the electrocardiogram in oncology clinical trials: focus on cardiac repolarization (QTc interval).

    Clinical pharmacology and therapeutics·2009
    Same author

    Cardiac repolarization and the safety of new drugs defined by electrocardiography.

    Clinical pharmacology and therapeutics·2006
    Same author

    Evaluation of the effect on cardiac repolarization (QTc interval) of oncologic drugs.

    Ernst Schering Research Foundation workshop·2006
    Same author

    Effects of supratherapeutic doses of ebastine and terfenadine on the QT interval.

    British journal of clinical pharmacology·2001

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • The clinical drug armamentarium has expanded, offering more antiarrhythmic agents.
    • Individualized therapy is crucial due to variable efficacy, toxicity, and mechanisms of action.
    • Sudden cardiac death prevention remains a critical challenge.

    Purpose of the Study:

    • To explore the potential of new antiarrhythmic agents, specifically class Ic drugs, in preventing sudden cardiac death.
    • To test the hypothesis that stabilizing electrical instability is key to reducing sudden cardiac death rates.

    Main Methods:

    • Utilizing new tools such as electrophysiological and Holter monitoring models.
    • Investigating the pharmacoelectrophysiological actions of novel antiarrhythmic agents.

    Main Results:

    Related Experiment Videos

    • Class Ic antiarrhythmic agents show promise in stabilizing cardiac electrical instability.
    • New approaches to preventing sudden cardiac death are emerging from advancements in tools and therapies.

    Conclusions:

    • Stabilizing electrical instability may be a vital strategy for preventing sudden cardiac death.
    • Advancements in antiarrhythmic drug development and monitoring tools offer new avenues for managing cardiac arrhythmias and preventing sudden death.